Apr 8 |
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
|
Apr 5 |
Goldman Sachs Predicts Over 120% Rally for These 2 ‘Strong Buy’ Stocks
|
Mar 28 |
Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path
|
Mar 11 |
Olema Pharmaceuticals GAAP EPS of -$0.49
|
Mar 11 |
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
|
Mar 6 |
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
|
Mar 4 |
Calculating The Intrinsic Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)
|
Feb 2 |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Jan 31 |
Olema Pharmaceuticals files to sell 13.21M common shares for holders
|
Jan 22 |
15 Small-Cap Stocks with High Potential
|